Press Releases May 6, 2026 04:01 PM

BridgeBio to Participate in May and June Investor Conferences

BridgeBio Pharma to Present at Major Healthcare Investor Conferences in May and June 2026

By Sofia Navarro BBIO

BridgeBio Pharma announces its upcoming participation in major healthcare investor conferences including BofA Securities, Jefferies Global Healthcare, and Goldman Sachs Global Healthcare Conferences. The company will showcase its focus on developing transformative medicines for genetic conditions through fireside chats and live webcasts, aiming to engage investors and highlight its innovative drug development approach.

BridgeBio to Participate in May and June Investor Conferences
BBIO

Key Points

  • BridgeBio Pharma will present at three major healthcare investor conferences in May and June 2026, offering insights via live webcasts and fireside chats.
  • The company focuses on developing medicines for genetic conditions using a decentralized, hub-and-spoke operational model for speed, precision, and scalability.
  • BridgeBio addresses the challenge of drug development for small patient populations, aiming to bring innovative treatments to underserved genetic conditions.

PALO ALTO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences:

  • BofA Securities Health Care Conference 2026, Las Vegas, NV: Tuesday, May 12 at 2:20 pm PDT
  • 2026 Jefferies Global Healthcare Conference, New York, NY: Thursday, June 4 at 11:05 am EDT
  • Goldman Sachs 47th Annual Global Healthcare Conference, Miami FL: Tuesday, June 9 at 8:00 am EDT

To access the live webcast of BridgeBio’s presentations, please visit the “Events and Presentations” page within the Investors section of the BridgeBio website at https://investor.bridgebio.com. A replay of the webcasts will be available on the BridgeBio website for 90 days following the event.

About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
[email protected]  
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
[email protected]


Risks

  • The commercial viability of developing drugs for small, underserved patient populations can be challenging, potentially impacting revenue and growth.
  • Successful translation of genetic science advancements into effective medicines depends on clinical, regulatory, and commercialization success, which carries inherent risks.
  • Market reception to investor presentations may be muted if new data, product updates, or financial guidance are not provided, limiting immediate stock impact.

More from Press Releases

NMI Holdings, Inc. to Participate in Upcoming Investor Conferences May 12, 2026 Fervo Energy Announces Pricing of its Upsized Initial Public Offering May 12, 2026 Titan Mining Delivers 22% Revenue Growth and Expands U.S. Critical Minerals Platform with Graphite Production May 12, 2026 Anteris Announces Results for the First Quarter of 2026 May 12, 2026 Copa Holdings Announces Monthly Traffic Statistics for April 2026 May 12, 2026